The FDA statement came a day after researchers at New York University released a study which said the rapid test might miss as many as half of positive cases.
In a written statement, Abbott officials said they are continuing 'to optimize this test as the world learns more about this virus,' but disputed the assertions of the NYU review.
“Abbott's ID NOW is the fastest molecular point-of-care rapid test available today and has been delivering reliable results when and where they're needed,” the company stated, putting some of the blame on how their rapid test is being utilized.
“We're seeing studies being conducted to understand the role of ID NOW in ways that it was not designed to be used,” the company added. “In particular, the NYU study results are not consistent with other studies.”
President Trump has often talked up the Abbott test as an indicator of how well the U.S. has responded to the virus threat.
"This is a five to 15-minute test," the President said on Monday about the Abbott test. "These tests are highly sophisticated -- very quick, very good. This is things that didn't even exist a short while ago."
"So we do have a great testing capability at the White House," Mr. Trump added.
President Trump has alternately trumpeted the growing testing capabilities in the U.S. - and bemoaned them as well.
"We have more cases than anybody in the world. But why? Because we do more testing," the President said during a stop in Pennsylvania on Thursday.
"When you test, you have a case. When you test, you find something is wrong with people. If we didn't do any testing we would have very few cases. They (the press) don't want to write that. It's common sense," Mr. Trump said.